GLPwatch
Gallbladder disease
1,927 FAERS reports across 7 drugs
Last updated 2026-05-28 15:46 UTCGallbladder disease refers to any condition that affects the small, pear-shaped organ under the liver that stores bile, often causing pain or digestive issues.
Plain-language definition of the term.
FDA labels for GLP-1 drugs including Byetta, Mounjaro, Ozempic, Rybelsus, Saxenda, Soliqua, Trulicity, Victoza, Wegovy, Xultophy, and Zepbound list gallbladder disease as an adverse reaction and include warnings about potential gallbladder-related side effects.
AI summary of the sources below.
FAERS report counts (as of 2026Q1) reflect voluntary adverse-event reports and cannot establish causation or true frequency; higher counts often track prescription volume. openFDA FAERS ↗
Reports by drug
| Drug | FAERS reports | Quarter |
|---|---|---|
| Ozempic | 456 | 2026Q1 |
| Mounjaro | 453 | 2026Q1 |
| Byetta | 359 | 2026Q1 |
| Victoza | 259 | 2026Q1 |
| Saxenda | 195 | 2026Q1 |
| Wegovy | 150 | 2026Q1 |
| Rybelsus | 55 | 2026Q1 |
Mentioned in FDA labels
Research mentioning gallbladder disease (5)
- Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
- The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study.
- Liraglutide-related cholelithiasis.
- Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy.
- Semaglutide Once Weekly Helps Adolescents Lose Weight, but 4% Developed Acute Cholelithiasis.